… drugs in three therapeutic classes approved by the FDA for the treatment of patients with
functional class III PAH. Rational therapeutic … patient's specific situation, clinical judgment, and …

… drugs that are in or are entering phase 3 clinical testing. … , anticoagulant, or fibrinolytic drugs.
Addressing these unmet … , and fibrinolytic drugs; and (3) provides clinical perspectives on …

… We now have new and improved chemotherapy drugs and targeted therapies that act at
a number of sites and by a variety of mechanisms to limit cancer cell proliferation. Yet while …

… the drug. Practical issues regarding dosing and frequency of infusions generate dilemmas in
clinical practice. … to the use and costs of the drug, and summarize its mechanisms of action. …

… remained off antihypertensive drug therapy than subjects without counselling (39 vs 5%;
P<0.001) although blood pressure control was better in subjects receiving drug therapy. In three …

… Since 2008, systemic therapy with the multikinase inhibitor … Since the introduction of
sorafenib into clinical practice, several … The development of drug treatments for HCC has been …

… of MMF can confer a clinical benefit, a monitoring strategy incorporating the full 12-hr AUC
is cumbersome and unsuitable for everyday clinical practice, particularly in the outpatient …

… Priority was given to RCTs included in clinical practice guidelines, systematic reviews, and
meta-analyses that had been updated with the most recent RCTs. If no RCT was found on a …

… In patients who are receiving dual antiplatelet drug therapy … antiplatelet therapy around the
time of surgery (Grade 2C). … who are receiving dual antiplatelet therapy and require surgery, …

… Elderly or cardiac patients with Graves’ disease may require antithyroid drug therapy before
treatment with radioactive iodine, to deplete the thyroid gland of stored hormone and reduce …